Novartis AG (NVS) Stock Forecast
NVS analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.42 / 5 from 12 analysts
- Price target
- $154.65 average of analyst targets
- Upside to target
- +2.7% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $2.25
- 52-week range
- $121.80 – $168.62
NVS analyst ratings
12 analystsNumber of analysts at each rating.
NVS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NVS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.24 | $2.22 | $2.26 | $2.25 | −0.4% | 3 |
| Current fiscal year (2026) | $8.83 | $8.60 | $9.04 | $8.98 | −1.7% | 9 |
| Next fiscal year (2027) | $9.80 | $9.30 | $10.79 | $8.83 | +11.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NVS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $14.61B | $14.35B | $15.06B | +1.8% | 8 |
| Current fiscal year (2026) | $57.66B | $56.11B | $59.88B | +1.7% | 21 |
| Next fiscal year (2027) | $61.34B | $59.23B | $64.00B | +6.4% | 21 |
NVS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NVS revenue: reported and forecast
NVS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.20 | $2.23 | $2.23 | $2.23 | $2.24 | +1.9% | 1 up · 0 down |
| Current fiscal year (2026) | $8.68 | $8.80 | $8.85 | $8.83 | $8.83 | +1.7% | 2 up · 2 down |
| Next fiscal year (2027) | $9.75 | $9.81 | $9.84 | $9.79 | $9.80 | +0.5% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NVS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NVS beat in 10 of 12.
What analysts expect from NVS
12 analysts cover Novartis; their consensus rating is hold (3.42 on a 1–5 scale, where 5 is a strong buy). The average price target is $154.65, 2.7% above the latest close of $150.62. Analysts expect earnings of $8.83 per share for 2026, −1.7% from a year earlier. For 2027 the average estimate is $9.80 per share on revenue of $61.3 billion. Novartis beat the EPS estimate in 10 of the last 12 quarters.
Related: NVS income statement, NVS key metrics, NVS chart. See the NVS stock overview for the latest quote and news.
NVS forecast FAQ
What is Novartis's price target?
The average analyst price target for Novartis is $154.65, 2.7% above the latest close of $150.62.
Is Novartis a buy, hold or sell?
Of 12 analysts covering Novartis, 2 rate it a strong buy, 3 a buy, 6 a hold, 0 a sell and 1 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Novartis's EPS forecast?
Analysts forecast $8.83 per share for 2026 (range $8.60 to $9.04); for 2027 the estimate is $9.80.
What is Novartis's revenue forecast?
The average revenue estimate for 2026 is $57.7 billion, growth of 1.7%; for 2027 it is $61.3 billion.
When does Novartis report earnings?
Novartis is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 before the market opens; the EPS estimate is $2.25.
Does Novartis usually beat earnings estimates?
Novartis reported EPS at or above the analyst estimate in 10 of the last 12 quarters.